Glaukos Corporation (NYSE:GKOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(c) Effective May 5, 2017, Richard L. Harrison retired as Glaukos
Corporations (the Companys) Chief Financial Officer, and Joseph
E. Gilliam became the Companys Chief Financial Officer and Senior
Vice President, Corporate Development.Mr. Harrisons planned
retirement had been announced by the Company in a Current Report
on Form 8-K filed with the Securities and Exchange Commission
(the Commission) on July 14, 2016.Mr. Gilliams expected
appointment to this role was previously announced by the Company
in a Current Report on Form 8-K filed with the Commission on
February 6, 2017.

Mr. Gilliam previously entered into an Offer Letter with the
Company, a summary of the terms of which was included in, and a
copy of which was attached as Exhibit 99.2 to the Current Report
on Form 8-K filed with the Commission on February 6, 2017.In
connection with his appointment, Mr. Gilliam entered into an
Executive Severance and Change in Control Agreement with the
Company, dated May 5, 2017 (the Severance Agreement), a copy of
which is attached to this Current Report as Exhibit 10.1. to the
terms of the Severance Agreement, if Mr. Gilliam is terminated as
a result of (i)an involuntary termination without cause or (ii)a
resignation for good reason (each as defined in the Severance
Agreement), then he will receive an amount equal to nine months
of his base salary amount in effect at the time of such
termination, paid in a lump sum on the 60thday following the date
of such termination. Mr. Gilliam (and his spouse and dependents)
will also receive medical and dental benefits provided by the
Company at least equal to the levels of benefits provided to our
similarly situated active employees until the earlier of (i)the
ninemonth anniversary of the date of such termination or (ii)the
date that he becomes covered under a subsequent employers medical
and dental benefits plans. Mr.Gilliam will also vest in all
equity and equitybased awards that would otherwise have vested
during the 12months following the date of such termination.

If Mr.Gilliam is terminated as a result of (i)an involuntary
termination without cause or (ii)a resignation for good reason,
in either case within three months prior or 12months following a
change in control (as defined in the Severance Agreement), then
he will receive an amount equal to the sum of (i) 12months of his
base salary amount in effect at the time of such termination, and
(ii)1.0 times his target annual bonus for the year in which the
change in control occurs, paid in a lump sum on the 60thday
following the date of such termination. Mr. Gilliam (and his
spouse and dependents) will also receive medical and dental
benefits provided by the Company at least equal to the levels of
benefits provided to our similarly situated active employees
until the earlier of (i)the 12month anniversary of the date of
such termination or (ii)the date that he becomes covered under a
subsequent employers medical and dental benefits plans. Mr.
Gilliam will also vest in all equity and equitybased awards
outstanding on the date of termination.

In the event that Mr.Gilliam would be subject to the excise tax
imposed by Section4999 of the Internal Revenue Code of 1986, as
amended (the Code) and the net aftertax benefit that he would
receive by reducing such payments to the threshold level as
determined by Section280G of the Code is greater than the net
aftertax benefit he would receive if the full amount of such
payments were made, then such payments will be reduced so that
such payments do not exceed the threshold level as determined by
Section280G of the Code.

All of the above benefits are subject to the executives execution
of a general release of claims in the Companys favor, and this
description of the terms of Mr. Gilliams Severance Agreement is
subject in all respects to the terms of the Severance Agreement.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Glaukos Corporation (NYSE:GKOS) Recent Trading Information

Glaukos Corporation (NYSE:GKOS) closed its last trading session down -0.92 at 41.69 with 3,579,439 shares trading hands.